1. Home
  2. ANNX vs CERT Comparison

ANNX vs CERT Comparison

Compare ANNX & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.79

Market Cap

972.5M

Sector

Health Care

ML Signal

HOLD

CERT

Certara Inc.

HOLD

Current Price

$6.23

Market Cap

860.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANNX
CERT
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
972.5M
860.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
ANNX
CERT
Price
$5.79
$6.23
Analyst Decision
Strong Buy
Buy
Analyst Count
6
10
Target Price
$16.50
$11.67
AVG Volume (30 Days)
2.2M
3.0M
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
87.50
EPS
N/A
N/A
Revenue
N/A
$418,838,000.00
Revenue This Year
N/A
$4.18
Revenue Next Year
$16,320.74
$5.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.75
52 Week Low
$1.60
$5.19
52 Week High
$7.18
$13.88

Technical Indicators

Market Signals
Indicator
ANNX
CERT
Relative Strength Index (RSI) 47.71 52.47
Support Level $4.79 $6.04
Resistance Level $6.56 $6.48
Average True Range (ATR) 0.29 0.29
MACD -0.06 0.05
Stochastic Oscillator 8.43 65.07

Price Performance

Historical Comparison
ANNX
CERT

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

Share on Social Networks: